FAST NEWS: Ascletis Pharma’s loss narrows as core product sales surge
The latest: Ascletis Pharma Inc. (1672.HK) announced Tuesday its net loss narrowed sharply in the first half of this year to 16.56 million yuan ($2.3 million) from an 88 million…
Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field
Global agreement for oral anti-viral comes just months after company signed separate similar tie-up for a Covid mRNA vaccine also in development Key Takeaways Everest has signed a global licensing…
RECENT ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Innogen Pharma jostles for a slice of the weight-loss market
-
Horizon’s lead grows in smart driving race with new product rollouts
9660.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
